Skip to main content
Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
102.02
-6.50 (-5.99%)
At close: Dec 5, 2025, 4:00 PM EST
101.99
-0.03 (-0.03%)
After-hours: Dec 5, 2025, 7:55 PM EST

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 2016 - 2020
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2016 - 2020
United States Revenue
851.33M697.16M
Log In
Log In
Log In
Upgrade
International Revenue
51.24M41.85M
Log In
Log In
Log In
Upgrade
Revenue (Total)
-739.02M
Log In
Log In
Log In
Upgrade

Revenue Breakdown

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 2015 - 2019
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 2015 - 2019
Revenue (Other)
739.02M
Log In
Log In
Log In
Upgrade
Revenue (Total)
739.02M
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 2015 - 2019
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 2015 - 2019
Precision Oncology Testing Revenue
687.94M
Log In
Log In
Log In
Upgrade
Development Services and Other Revenue
51.08M
Log In
Log In
Log In
Upgrade
Revenue (Total)
739.02M
Log In
Log In
Log In
Upgrade

Gross Profit

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 2015 - 2019
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 2015 - 2019
Precision Oncology Testing Gross Profit
427.36M
Log In
Log In
Log In
Upgrade
Development Services and Other Gross Profit
21.86M
Log In
Log In
Log In
Upgrade
Gross Profit (Total)
449.22M
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 2016 - 2020
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2016 - 2020
Clinical Test Sales Volume
254.30K206.70K
Log In
Log In
Log In
Upgrade
Biopharmaceutical Test Sales Volume
-40.50K
Log In
Log In
Log In
Upgrade